Ocrelizumab reduces progression of brain atrophy in patients with multiple sclerosis
Introduction: Multiple sclerosis (MS) is a clinical entity characterised by both inflammatory and neurodegenerative components. Ocrelizumab is an anti-CD20 monoclonal antibody that has demonstrated high clinical efficacy in controlling neuroinflammation, and evidence suggests it may also exert a ben...
-д хадгалсан:
| Үндсэн зохиолч: | |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Elsevier
2026-04-01
|
| Цуврал: | Neurology Perspectives |
| Нөхцлүүд: | |
| Онлайн хандалт: | http://www.sciencedirect.com/science/article/pii/S2667049625000341 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|